Literature DB >> 3391108

Individualized aminoglycoside dosage regimens in patients with cystic fibrosis.

G Delage1, L Desautels, S Legault, R Lasalle, J G Lapierre, A Lamarre, P Masson, S Spier.   

Abstract

Individualized dosage regimens have recently been recommended for patients treated with aminoglycoside antibiotics. We have developed a calculator-based program for our patients with cystic fibrosis and have studied 93 courses of intravenous aminoglycoside treatment, comparing predicted and measured values in 45 courses. Pharmacokinetic parameters differed notably among subjects: this was reflected by widely variable total daily aminoglycoside dosage requirements. The mean daily dosage requirements (+/- SD) for tobramycin (62 treatment courses) was 13.0 +/- 3.74 mg/kg, and for gentamicin (26 treatment courses) was 11.5 +/- 2.6 mg/kg. The accuracy of the program was evaluated by its ability to predict peak and trough values in individuals: 84 percent of measured peaks were within 2 micrograms/ml of the predicted level. Nephrotoxicity was observed in one patient, ototoxicity in three. This program provides a simple, safe, and effective method of tailoring an aminoglycoside regimen to the patient's needs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391108     DOI: 10.1177/106002808802200504

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  Aminoglycoside therapy: current and prospective uses.

Authors:  J E Leggett
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Aminoglycoside therapy. Current use and future prospects.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1990-06-22

Review 3.  Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.

Authors:  D J Touw; A A Vinks; J W Mouton; A M Horrevorts
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 4.  Pharmacokinetics of anti-infective agents in paediatric patients.

Authors:  D R Butler; R J Kuhn; M H Chandler
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.